A Single Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study of the Effects of HKI-272 on Cardiac Repolarization in Healthy Adult Subjects
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment
QTc interval
3 days
Yes
Puma
Study Director
Biotechnology
United States: Food and Drug Administration
3144A1-105
NCT00708903
May 2008
July 2008
Name | Location |
---|---|
Seattle, Washington 98195 |